Galapagos and Cellzome enter kinase drug R&D accord

Belgian drug discovery firm Galapagos NV and Boston, USA-based Cellzome have entered a kinase drug discovery collaboration. Under the terms of the deal, Galapagos' service division, BioFocus DPI, will give Cellzome access to its SoftFocus kinase libraries and provide biological screening and chemistry expertise to find inhibitors of Cellzome's kinase targets. In this service contract, BioFocus DPI will receive an upfront payment for the library access as well as research fees. Further financial terms of the agreement were not dicslosed.